Compare Digital Realty Trust, Inc. (DLR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs TG Therapeutics Inc — how do they compare? Digital Realty Trust, Inc. trades at $191.45 (market cap $70.61B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Digital Realty Trust, Inc. is far larger — about 9.2× TG Therapeutics Inc's market cap, and Digital Realty Trust, Inc. pays a 2.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DLR | TGTX | |
|---|---|---|
Market Cap | $70.61B | $7.64B |
Sector | Real Estate | Health |
52-Week High | $203.91 | $59.06 |
52-Week Low | $147.93 | $26.94 |
Enterprise Value | $89.32B | $7.84B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty (DLR) trades at $196.84, up 2.9% with bullish technical signals and strong analyst support. The stock shows robust fundamentals with revenue growth from $5.6B in 2024 to $6.1B in 2025 and net income reaching $1.31B. Recent Q2 2026 earnings beat expectations with $1.21 EPS versus $0.48 expected, driven by record leasing activity and AI-driven data center demand. The company maintains a 63.8% buy rating from analysts with a $216.56 consensus target.
DLR presents a compelling growth opportunity leveraging AI infrastructure demand, though premium valuation metrics (P/E 241.53, P/S 25.08) warrant caution. Key risks include high debt levels ($15.1B long-term) and cyclical tech spending. Current price near the $197 low target suggests limited downside with 10% upside to consensus target, supported by strong cash flow generation and dividend payments.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
